Understanding and targeting alkylator resistance in glioblastoma
Summary: Alkylating chemotherapy is the mainstay in the treatment of pediatric and adult glioblastoma despite primary and acquired resistance and scientific efforts to precisely define therapies for individual patients. A focus on non-MGMT-mediated temozolomide resistance for pediatric glioblastoma...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 1, 2014
|
| In: |
Cancer discovery
Year: 2014, Volume: 4, Issue: 10, Pages: 1120-1122 |
| ISSN: | 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-14-0918 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/2159-8290.CD-14-0918 Verlag, lizenzpflichtig, Volltext: https://cancerdiscovery.aacrjournals.org/content/4/10/1120 
|
| Author Notes: | Wolfgang Wick and Michael Platten |
| Summary: | Summary: Alkylating chemotherapy is the mainstay in the treatment of pediatric and adult glioblastoma despite primary and acquired resistance and scientific efforts to precisely define therapies for individual patients. A focus on non-MGMT-mediated temozolomide resistance for pediatric glioblastoma suggests options for new drug combinations. Cancer Discov; 4(10); 1120-2. ©2014 AACR. - See related article by Agnihotri et al., p. 1198 |
|---|---|
| Item Description: | Gesehen am 15.07.2020 |
| Physical Description: | Online Resource |
| ISSN: | 2159-8290 |
| DOI: | 10.1158/2159-8290.CD-14-0918 |